A New Cancer Treatment Has Given Terminal Patients a Second Chance at Life – Futurism

Could This Treatment Cure Cancer?

Despite the many advances in medicine over the last century, a cure for one of the most prevalent and devastating diseases in the world todaycontinues to evade us. But thanks to new research, that could soon change.

Kite Pharma, a US pharmaceutical company, just released the groundbreaking results of their six-month gene therapy trial: terminal cancer patients incomplete remission after just a single round.

The treatment filters a patients blood to remove T-cells, immune system cells that can be genetically engineered in a lab to identify cancer cells. Cancer cells thrive because of their ability to evade the immune system.This new therapy boosts immune cells so that they are able to eliminate cancer cells more effectively.

Patients who participated in the trial had one of three types of non-Hodgkin lymphoma. The advanced stageof their conditions meant all of them were given only a few months to live. However, following the first round of gene therapy, which took place nine months after the trial began, half the patients are not only still alive, but a third of themappear to be cured.

Among them is a 43- year-old named Dimas Padilla from Orlando, Florida whose cancer had stopped responding to chemotherapy. He completed the first round of the trials treatment last August, and his cancer is now in remission.

These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma, said head cancer information nurse, Martin Ledwick from the Cancer Research UK, in an interview with The Telegraph.

While the results are promising and could prove to be life- changing for patients with terminal cancer, the treatment is not without risks.

Because the therapy essentially puts the human immune system to go into overdrive by radically altering human cells, complications are certainly possible some of which could be fatal. In fact, during the trial, two people diedas a resultof the therapy not because of the cancer. Some patientsimmune systems overreacted in its effort to kill the cancer cells, while others developed blood-count related issues such as anemia. Reports of patients suffering from neurological problems were also cited, but these side effectsapparently only lasted a few days.

More studies are needed tounderstand the therapys side effects, potential complications, and long-term benefits.

The trials full results wont be presented until April, and the pharmaceutical company still has to get approval from the European regulatory boards which means it will be a while yet before the therapy becomes available. Given the possible risks, it might give them enough time to study the therapy further and refine the process hopefully eliminating any adverse effects.

Although, as the Cancer Institutes Dr. Steven Rosenberg points out: Its a safe treatment, certainly a lot safer than having progressive lymphoma.

Excerpt from:
A New Cancer Treatment Has Given Terminal Patients a Second Chance at Life - Futurism